Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric J Small

Showing results (251-260 of 361) with videos related to

Pageof 37
Sort By:
European Urology|July 13, 2016
Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302Johann S de Bono, Matthew R Smith, Fred Saad, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 11, 2021
Blood Biomarker Landscape in Patients with High-risk Nonmetastatic Castration-Resistant Prostate Cancer Treated with Apalutamide and Androgen-Deprivation Therapy as They Progress to Metastatic DiseaseMatthew R Smith, Shibu Thomas, Michael Gormley, et al.
Journal of the National Cancer Institute|April 20, 2006
Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16Daniel P Petrylak, Donna Pauler Ankerst, Caroline S Jiang, et al.
Cancer Immunology Research|October 1, 2016
Systemic GM-CSF Recruits Effector T Cells into the Tumor Microenvironment in Localized Prostate CancerXiao X Wei, Stephen Chan, Serena Kwek, et al.
Journal of Immigrant and Minority Health|November 7, 2022
Assessing Unique Risk Factors for COVID-19 Complications Among Cancer Patients: A Multi-ethnic Cohort StudyHala T Borno, Mi-Ok Kim, Irina Tolstykh, et al.
The Journal of Urology|July 19, 2008
von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinomaToni K Choueiri, Susan A J Vaziri, Erich Jaeger, et al.
JAMA Network Open|October 15, 2024
Prior Local Therapy and First-Line Apalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer: A Secondary Analysis of the SPARTAN Randomized Clinical TrialSoumyajit Roy, Shawn Malone, Kevin Wing, et al.
European Urology Oncology|December 10, 2023
Post Hoc Analysis of Rapid and Deep Prostate-specific Antigen Decline and Patient-reported Health-related Quality of Life in SPARTAN and TITAN Patients with Advanced Prostate CancerEric J Small, Kim N Chi, Simon Chowdhury, et al.
Cancer|November 25, 2014
Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance)Jai N Patel, Chen Jiang, Daniel L Hertz, et al.
Molecular Cancer Research : MCR|June 9, 2017
Real-Time Transferrin-Based PET Detects MYC-Positive Prostate CancerRahul Aggarwal, Spencer C Behr, Pamela L Paris, et al.
Pageof 37

Showing results (251-260 of 361) with videos related to

Sort By:
Pageof 37
European Urology|July 13, 2016
Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302Johann S de Bono, Matthew R Smith, Fred Saad, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 11, 2021
Blood Biomarker Landscape in Patients with High-risk Nonmetastatic Castration-Resistant Prostate Cancer Treated with Apalutamide and Androgen-Deprivation Therapy as They Progress to Metastatic DiseaseMatthew R Smith, Shibu Thomas, Michael Gormley, et al.
Journal of the National Cancer Institute|April 20, 2006
Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16Daniel P Petrylak, Donna Pauler Ankerst, Caroline S Jiang, et al.
Cancer Immunology Research|October 1, 2016
Systemic GM-CSF Recruits Effector T Cells into the Tumor Microenvironment in Localized Prostate CancerXiao X Wei, Stephen Chan, Serena Kwek, et al.
Journal of Immigrant and Minority Health|November 7, 2022
Assessing Unique Risk Factors for COVID-19 Complications Among Cancer Patients: A Multi-ethnic Cohort StudyHala T Borno, Mi-Ok Kim, Irina Tolstykh, et al.
The Journal of Urology|July 19, 2008
von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinomaToni K Choueiri, Susan A J Vaziri, Erich Jaeger, et al.
JAMA Network Open|October 15, 2024
Prior Local Therapy and First-Line Apalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer: A Secondary Analysis of the SPARTAN Randomized Clinical TrialSoumyajit Roy, Shawn Malone, Kevin Wing, et al.
European Urology Oncology|December 10, 2023
Post Hoc Analysis of Rapid and Deep Prostate-specific Antigen Decline and Patient-reported Health-related Quality of Life in SPARTAN and TITAN Patients with Advanced Prostate CancerEric J Small, Kim N Chi, Simon Chowdhury, et al.
Cancer|November 25, 2014
Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance)Jai N Patel, Chen Jiang, Daniel L Hertz, et al.
Molecular Cancer Research : MCR|June 9, 2017
Real-Time Transferrin-Based PET Detects MYC-Positive Prostate CancerRahul Aggarwal, Spencer C Behr, Pamela L Paris, et al.
Pageof 37